Microparticles in Cirrhosis and Portal Hypertension (MicroCir)
Primary Purpose
Liver Cirrhosis, Portal Hypertension
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
research on interactions between portal hypertension and microparticles
Sponsored by
About this trial
This is an interventional basic science trial for Liver Cirrhosis
Eligibility Criteria
Inclusion Criteria:
- Non infected cirrhotic patient (30 patients Child-Pugh A, 30 Child-Pugh B et 30 Child-Pugh C).
- 10 heathly volunteer (groupe contrôle).
Exclusion Criteria:
- legal incapacity or limited legal capacity
- Subject unlikely to cooperate in the study and / or low early cooperation by the investigator
- Subject without health insurance
- Pregnant woman
- About being in the disqualification of another study or under the "national register of volunteers."
- Any proven or suspected infection
- Pre-hepatic portal hypertension (door thrombosis) or post-liver (Budd-Chiari) transplant patients, HIV infection (also refusing HIV status) or patients on immunosuppressive therapies (including corticosteroids) interferon taken
- Treatment with anticoagulants or antiplatelet upper gastrointestinal bleeding in the two months prior
- Patients with TIPS
- Any cancer pathology proven and current.
- Chronic heart failure (stage III or IV of the classification of the New York Heart Association [NYHA])
- Inability to receive clear information in patients with severe encephalopathy and do not have someone you trust
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
cirrhotic patients
healthy volunteers
Arm Description
We prospectively included 90 cirrhotic patients .
The pilot cohort was compared with 10 healthy volunteers.
Outcomes
Primary Outcome Measures
Level of expression of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
Procoagulant activity of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
Secondary Outcome Measures
Full Information
NCT ID
NCT02859610
First Posted
July 28, 2016
Last Updated
August 4, 2016
Sponsor
Centre Hospitalier Universitaire de Besancon
1. Study Identification
Unique Protocol Identification Number
NCT02859610
Brief Title
Microparticles in Cirrhosis and Portal Hypertension
Acronym
MicroCir
Official Title
Characterization of Microparticles in Cirrhosis and Portal Hypertension With Implications
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
research on interactions between portal hypertension and microparticles
Detailed Description
It has already been shown that increased certain markers of stress, such as prolonged elevation of CRP in the absence of bacterial infection, increased free cortisol and serum copeptin, are associated with an excess of mortality in cirrhosis.
MPs are membrane vesicles of variable size between 0.1 and 1 .mu.m, released into the extracellular space following activation or cellular apoptosis. MPs are also found in the circulating blood of healthy volunteers and their plasma levels rise in certain diseases to increased thrombotic risk, such as in cancer. Their membrane is composed of antigens whose organization is characteristic of the parent cell and negatively charged phospholipids, phosphatidylserines, conferring pro-coagulant properties to these MPs.
Currently, work on the MPs are increasing following the discovery of their involvement in physiological processes such as proliferation, differentiation, cell activation and immune response but it is certainly their pro-thrombogenic power that was the most studied.
Recent studies have also implicated MPs in the pathophysiology of chronic liver disease. Cirrhotic patients have elevated concentrations of MPs from leukocytes, endothelial cells and hepatocytes compared to control subjects, and concentrations of MPs increase with worsening liver function. Increasing MPs during the cirrhosis may be related on the one hand with a decreased clearance and secondly with an excess of proinflammatory cytokines by increasing the phenomenon of intestinal bacterial translocation. The assumption of the role of systemic inflammation in the training of MPs is reinforced by the existence of a significant correlation between the original MPs hepatocyte or buffy endothelial and CRP Thus, the increase in MPs observed with the increase of PH could increase the risk of thrombosis in intestinal microcirculation leading to enterocytic suffering from ischemic, reflected by an increase in serum concentrations of I-FABP ( intestinal fatty acid binding protein). This suffering enterocytes leads to increased intestinal bacterial translocation and ultimately to increased formation of MPs. These MPs could also worsen liver function by the same phenomenon of thrombosis in the hepatic microcirculation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cirrhosis, Portal Hypertension
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
cirrhotic patients
Arm Type
Other
Arm Description
We prospectively included 90 cirrhotic patients .
Arm Title
healthy volunteers
Arm Type
Other
Arm Description
The pilot cohort was compared with 10 healthy volunteers.
Intervention Type
Other
Intervention Name(s)
research on interactions between portal hypertension and microparticles
Primary Outcome Measure Information:
Title
Level of expression of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
Time Frame
one year
Title
Procoagulant activity of microparticles in cirrhotic patients with hepatic function of varying severity (Child- Pugh A to C) and in 10 healthy controls.
Time Frame
one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Non infected cirrhotic patient (30 patients Child-Pugh A, 30 Child-Pugh B et 30 Child-Pugh C).
10 heathly volunteer (groupe contrôle).
Exclusion Criteria:
legal incapacity or limited legal capacity
Subject unlikely to cooperate in the study and / or low early cooperation by the investigator
Subject without health insurance
Pregnant woman
About being in the disqualification of another study or under the "national register of volunteers."
Any proven or suspected infection
Pre-hepatic portal hypertension (door thrombosis) or post-liver (Budd-Chiari) transplant patients, HIV infection (also refusing HIV status) or patients on immunosuppressive therapies (including corticosteroids) interferon taken
Treatment with anticoagulants or antiplatelet upper gastrointestinal bleeding in the two months prior
Patients with TIPS
Any cancer pathology proven and current.
Chronic heart failure (stage III or IV of the classification of the New York Heart Association [NYHA])
Inability to receive clear information in patients with severe encephalopathy and do not have someone you trust
12. IPD Sharing Statement
Learn more about this trial
Microparticles in Cirrhosis and Portal Hypertension
We'll reach out to this number within 24 hrs